Navigation Links
Immucor Closes BioArray Acquisition
Date:8/5/2008

NORCROSS, Ga., Aug. 5 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has closed its previously-announced acquisition of BioArray Solutions Ltd.

Gioacchino De Chirico, President & CEO of Immucor, said, "We are pleased to have completed this acquisition, which we believe will enable us to provide innovative molecular diagnostic solutions for blood transfusions to enhance patient outcomes."

Immucor expects to provide more information about the BioArray acquisition on its investors conference call in October to review the results of its first fiscal quarter.

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.

For more information on Immucor, please visit our website at http://www.immucor.com .

Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Factors related to the BioArray acquisition that could adversely affect the Company's results include but are not limited to: the ability of the Company to successfully develop an automated platform for BioArray's transfusion genotyping system, and the cost to do so; the ability of the Company to gain FDA clearance for that automated platform; the acceptance of BioArray technology in transfusion and transplantation markets; and the cost to successfully market and sell products incorporating BioArray technology. Further risks concerning the Company's business are detailed in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on any forward-looking statements. Immucor assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Immucor Schedules Fiscal 2009 Guidance Call
2. Immucor Responding to FDA Warning Letter
3. Immucor Announces Record Fiscal Third Quarter Results
4. Immucor Schedules Third Quarter Earnings Release and Conference Call
5. Immucor, Inc. Adds Director to Board
6. Immucor Announces Update to Second Quarter Conference Call Number
7. Immucor, Inc. Appoints New Chief Financial Officer
8. Immucor Announces Record Fiscal First Quarter Revenues
9. Immucor Schedules First Quarter Earnings Release and Conference Call
10. NBTY Closes on Purchase of Leiner Health Products
11. Retired Respironics Chairman Jerry McGinnis and Renal Solutions CEO Pete DeComo Join ALung Technologies Board of Directors; ALung Closes on $1 Million Bridge Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: